Alignment is becoming a leadership priority for Danish life science.
Anders Thelborg has been re-elected as chair of Lif’s board and says he feels even better prepared to lead in what he calls “the most challenging time ever” for the industry. He highlights MFN as a potentially major disruption during his 25+ years in pharma.
Thelborg also points to reputation and public understanding as ongoing priorities. He asks why Lif is not more visible in Danish media to explain the value of a strong life science sector for productivity, tax revenue, and jobs.
What he highlights for the next period:
-
MFN agenda and recognition of the value of medicines as a fixed point.
-
A healthy Lif group, including supporting Thomas Senderovitz, newly appointed CEO.
-
Stronger cooperation with Dansk Industri and Dansk Erhverv to align messages and avoid “pulling in all directions”.
He adds that Lif exists for its members and will actively listen to their concerns and perspectives.
Read more at https://www.lif.dk/genvalgt-lif-forperson-vi-har-ikke-raad-til-at-stritte-i-alle-retninger/
